Malaria
Conditions
Interventions
Dihydroartemisinine/piperaquine
Sponsors
Improving Malaria Care (IMC Project)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age, 6¿59 months, Mono-infection with P. falciparum detected by microscopy; Asexual parasite count of 2000¿200 000/¿l Axillary temperature ¿ 37.5 °C or history of fever during the previous two weeks; Hemoglogin ¿ 8g/dl Ability to swallow oral medication; Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule; Informed consent from a parent or guardian in the case of children
Exclusion criteria
Exclusion criteria: Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO Body weight less than 5 kg; Presence of severe malnutrition (defined as a child whose growth standard is below ¿3 z-score); Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea withdehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS); Regular medication, which may interfere with antimalarial pharmacokinetics; History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s) Known individual or familly history of clinically significant prolonged QTc or subite death Previous particpation to malaria vaccine trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adequate clinical and parasitological response at day 28 PCR-corrected.;Late treatment failure;Early treatment failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Adequate clinical and parasitological response at day 42, PCR-corrected.;Fever clearance;Parasite clearance;Nature and incidence of adverse events | — |
Countries
Burkina Faso
Contacts
Public ContactOusmane Badolo
Outcome results
None listed